LenioBio

LenioBio is a private, platform-focused biotech company based in Aachen, Germany, that is commercializing its innovative ALiCE® (Almost Living Cell-Free Expression) technology. This eukaryotic, cell-free system enables the rapid production of complex, functional proteins—including challenging targets like GPCRs and antibodies—within 24 hours, without the need for cell line development. The company operates both a platform/product business model and a services arm (ALiCE® as a Service), targeting significant bottlenecks in biologics discovery and development. With strategic partnerships, non-dilutive funding from entities like the EU and CEPI, and a focus on scalability, LenioBio is positioned to disrupt traditional protein production workflows.

ALiCE® (Almost Living Cell-Free Expression): A proprietary, plant-based (Nicotiana tabacum), eukaryotic cell-free protein synthesis platform capable of rapid (24-hour), scalable production of complex proteins with native post-translational modifications, including antibodies, membrane proteins (GPCRs, RTKs), and toxic proteins.

LenioBio competes with traditional mammalian cell culture systems (e.g., CHO, HEK) and other cell-free expression platforms, both prokaryotic (e.g., E. coli lysate) and eukaryotic. Its key differentiators are its eukaryotic PTM capability, high yield, plant-based origin, and claimed seamless scalability from micro to liter scale.